Topic: acute kidney injury
The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.
Potrero Medical has been working to fully automate one of the last remaining vital signs collected in the hospital—urine output and the health of the kidney—by gathering data through a sensor-laden update to the 100-year-old indwelling foley catheter.
Potrero raised $26.6 million to help bring automation to the last remaining major vital sign, urine output, aiming to predict kidney injuries earlier.
The Dutch biotech's recAP candidate has shown a 40% reduction in mortality in patients with sepsis-related acute kidney injury.
Osprey Medical has raised $17.5 million for its device that makes a heart procedure safer for patients with chronic kidney disease.
The Novartis-partnered p53 gene-targeting siRNA cut the rate of acute kidney injury in patients following cardiac surgery.
Massachusetts biotech Sentien has filed for approval to start clinical trials of a blood filtering device packed with bone marrow cells for severe cases of acute kidney injury.
RenalGuard Solutions raised $14.5 million in a Series A round. The funds will support the pivotal trial of a device that protects the kidneys.
NeuroVive Pharmaceutical has terminated development of its cyclosporine formulation in acute kidney injury after the drug failed in a Phase II trial.